Richmond Brothers, owner of 10.8% of Rockwell Medical's outstanding shares, disclosed last night in a regulatory filing that it has concluded the company "continues to blatantly disregard the will" of its shareholders. Richmond added that it has "lost all confidence" in Chairman and CEO Robert Chioini's ability to effectively oversee the company and drive shareholder value. The fund stated, "Given the Issuer's significant financial and stock price underperformance and inability to monetize promising drugs Triferic and Calcitriol under Mr. Chioini's leadership, the Reporting Persons do not believe Mr. Chioini has proven himself capable of successfully leading the Company forward and are convinced that he should be replaced as Chairman and CEO immediately. To the extent this does not happen , the Reporting Persons note that Mr. Chioini, along with long-standing director Patrick J. Bagley, will be up for election at the 2018 annual meeting of shareholders, at which the Reporting Persons intend to nominate a competing slate of director candidates. Separate and apart from the Ravich Parties, the Richmond Parties intend to engage in discussions with shareholders of the Issuer, private equity firms, potential sources of financing and other interested parties regarding the Issuer's capital allocation, corporate governance and other means to enhance shareholder value, including a possible sale of the Issuer. While the Richmond Parties are not advocating for a sale of the Issuer at this time, the Richmond Parties believe there are multiple paths to value creation and that all paths should be evaluated. To the extent there is strategic interest in the Issuer, the Richmond Parties invite potential strategic acquirers to contact the Richmond Parties."